NASDAQ:EKSO Ekso Bionics - EKSO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ekso Bionics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.70 0.00 (0.00%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.70▼$1.7750-Day Range$1.04▼$1.8852-Week Range$1.03▼$3.15Volume30,066 shsAverage Volume53,570 shsMarket Capitalization$22.34 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Ekso Bionics MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside429.4% Upside$9.00 Price TargetShort InterestHealthy0.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.46Based on 10 Articles This WeekInsider TradingSelling Shares$15,464 Sold Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.95 out of 5 starsMedical Sector545th out of 1,028 stocksGeneral Industrial Machinery, Industry4th out of 10 stocks 3.5 Analyst's Opinion Consensus RatingEkso Bionics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $9.00, Ekso Bionics has a forecasted upside of 429.4% from its current price of $1.70.Amount of Analyst CoverageEkso Bionics has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.61% of the float of Ekso Bionics has been sold short.Short Interest Ratio / Days to CoverEkso Bionics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ekso Bionics has recently increased by 36.38%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldEkso Bionics does not currently pay a dividend.Dividend GrowthEkso Bionics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EKSO. Previous Next 1.9 News and Social Media Coverage News SentimentEkso Bionics has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Ekso Bionics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for EKSO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Ekso Bionics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ekso Bionics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $15,464.00 in company stock.Percentage Held by InsidersOnly 3.05% of the stock of Ekso Bionics is held by insiders.Percentage Held by InstitutionsOnly 12.74% of the stock of Ekso Bionics is held by institutions. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Ekso Bionics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ekso Bionics is -1.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEkso Bionics has a P/B Ratio of 0.58. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ekso Bionics (NASDAQ:EKSO) StockEkso Bionics Holdings, Inc. engages in the design, development and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. It operates through the following segments: EksoHealth and EksoWorks. The EksoHealth segment consists of the engineering, manufacture, and sale of exoskeletons for applications in the medical markets. The EksoWorks segment offers exoskeleton devices to allow able-bodied users to perform heavy duty work for extended periods. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.Read More Receive EKSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter. Email Address EKSO Stock News HeadlinesFebruary 5, 2023 | marketwatch.comWith Astonishing CAGR, Medical Exoskeleton Robots Market Generate Revenue at Significant Rate, 2029February 4, 2023 | marketwatch.comMedical Robotics Market (New Report) to Witness A Pronounce Growth During 2023-2029February 5, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...February 3, 2023 | marketwatch.comWith Astonishing CAGR, Passive Exoskeleton Market Generate Revenue at Significant Rate, 2029February 2, 2023 | marketwatch.comTelemedicine Robots Market to Grow Significantly by Leading Players 2023 to 2028February 2, 2023 | americanbankingnews.comStockNews.com Initiates Coverage on Ekso Bionics (NASDAQ:EKSO)January 31, 2023 | marketwatch.comExoskeleton Market 2023 Trend and Forecast Analysis by 2029 - Cyberdyne, Hocoma, ReWalk Robotics, Ekso BionicsJanuary 30, 2023 | marketwatch.comArtificial Organs Market 2023 Company Challenges, Latest Advancements, Growth Prediction, and Forecast by 2028February 5, 2023 | Tradewins (Ad)Know Your Profit Potential BEFORE You Trade!I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! January 30, 2023 | benzinga.comRehabilitation Equipment Market Size to Reach USD 23.73 Billion in 2030 | Emergen ResearchJanuary 30, 2023 | marketwatch.comRehabilitation Robotics Market Trends 2023-2029 by Key Players - AlterG, Bionik, Ekso Bionics, MyomoJanuary 30, 2023 | marketwatch.comPowered Exoskeleton Market High Growth Opportunities 2023 | CAGR Status, Industry Changing Dynamics, and Size Forecast to 2027January 28, 2023 | americanbankingnews.comShort Interest in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) Expands By 36.4%January 26, 2023 | marketwatch.comForecast 2028 for the Telemedicine Robots Market in terms of Size, Profits, Gross Margin, and Market shareJanuary 26, 2023 | americanbankingnews.comEkso Bionics (NASDAQ:EKSO) Now Covered by Analysts at StockNews.comJanuary 26, 2023 | marketwatch.comWearable Robotic Exoskeleton Market 2023 : Opportunities in Future, Business Growth Analysis by Top Countries Data and Industry Players by 2028January 24, 2023 | marketwatch.comBalance Rehabilitation Machine Market : A Comprehensive Analysis of the Global Industry from 2023 to 2029, Including Size, Share, Growth, and TrendsJanuary 23, 2023 | msn.comFDA clears Wandercraft's exoskeleton for stroke patient rehabJanuary 19, 2023 | marketwatch.comBionic Exoskeletons Market: 2023 [Latest Report] By Top Leading Players Analysis Till 2028January 18, 2023 | marketwatch.comSocially Assistive Healthcare Assistive Robot Market : Share, Industry Size, Opportunities, Analysis and Forecast to 2028 with Top Countries DataJanuary 18, 2023 | marketwatch.comHumanoid Healthcare Assistive Robot Market Share 2023 Comprehensive Insights, Innovations and Business Outlook till 2028January 15, 2023 | marketwatch.comRobotic Exoskeletons Market Size 2023 with strong supplier, Key factors, driving the market growth, Information 2028January 13, 2023 | marketwatch.comBionic Exoskeletons Market Size, Share 2023 : Industry Growing Rapidly with Recent Trends, Development, Revenue by 2028January 12, 2023 | marketwatch.comGlobal Smart Upper Limb Exoskeleton Market Size 2023 Research Report by Market Dynamics, Drivers, Opportunities, SWOT Analysis and Forecast to 2028January 12, 2023 | marketwatch.comHuman Augmentation Market Size, Status, Global outlook 2023 To 2029January 12, 2023 | marketwatch.comExoskeleton Robots Market Set For Rapid Growth and Competitive Landscape: Cyberdyne, Hocoma, ReWalk Robotics, Ekso BionicsJanuary 9, 2023 | marketwatch.comRehabilitation Robotics Market Segmentation, Future Trends, Growth Overview, Key Companies and Forecast by 2028See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EKSO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ekso Bionics and its competitors with MarketBeat's FREE daily newsletter. Email Address EKSO Company Calendar Last Earnings11/01/2021Today2/05/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry General industrial machinery, Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EKSO Previous SymbolOTCMKTS:EKSOD CUSIPN/A CIK1549084 Webwww.eksobionics.com Phone(510) 984-1761Fax510-927-2647Employees55Year FoundedN/APrice Target and Rating Average Stock Price Forecast$9.00 High Stock Price Forecast$9.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+429.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-9,760,000.00 Net Margins-109.88% Pretax Margin-109.88% Return on Equity-45.07% Return on Assets-34.09% Debt Debt-to-Equity RatioN/A Current Ratio4.68 Quick Ratio4.23 Sales & Book Value Annual Sales$11.25 million Price / Sales1.99 Cash FlowN/A Price / Cash FlowN/A Book Value$2.94 per share Price / Book0.58Miscellaneous Outstanding Shares13,140,000Free Float12,741,000Market Cap$22.34 million OptionableNot Optionable Beta1.70 Key ExecutivesScott DavisChief Executive Officer & DirectorJerome WongChief Financial Officer, Secretary & ControllerCharlie WuSenior Director-OperationsStephan AderholdVice President-EMEA Sales & MarketingJason JonesVice President-Product DevelopmentKey CompetitorsMarker TherapeuticsNASDAQ:MRKRAcorda TherapeuticsNASDAQ:ACORBabylonNYSE:BBLNeFFECTOR TherapeuticsNASDAQ:EFTRLannettNYSE:LCIView All CompetitorsInsiders & InstitutionsEssex Investment Management Co. LLCBought 124,384 shares on 2/3/2023Ownership: 3.379%Simplex Trading LLCSold 11,100 shares on 2/2/2023Ownership: 0.000%Legato Capital Management LLCBought 37,497 shares on 2/1/2023Ownership: 0.285%Strategic Wealth Investment Group LLCBought 5,917 shares on 1/27/2023Ownership: 0.216%Steven ShermanSold 10,576 sharesTotal: $13,537.28 ($1.28/share)View All Insider TransactionsView All Institutional Transactions EKSO Stock - Frequently Asked Questions Should I buy or sell Ekso Bionics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ekso Bionics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" EKSO shares. View EKSO analyst ratings or view top-rated stocks. What is Ekso Bionics' stock price forecast for 2023? 1 equities research analysts have issued 12-month price objectives for Ekso Bionics' shares. Their EKSO share price forecasts range from $9.00 to $9.00. On average, they expect the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 429.4% from the stock's current price. View analysts price targets for EKSO or view top-rated stocks among Wall Street analysts. How have EKSO shares performed in 2023? Ekso Bionics' stock was trading at $1.19 on January 1st, 2023. Since then, EKSO stock has increased by 42.9% and is now trading at $1.70. View the best growth stocks for 2023 here. Are investors shorting Ekso Bionics? Ekso Bionics saw a increase in short interest during the month of January. As of January 15th, there was short interest totaling 68,600 shares, an increase of 36.4% from the December 31st total of 50,300 shares. Based on an average daily volume of 52,800 shares, the short-interest ratio is currently 1.3 days. Currently, 0.6% of the company's shares are sold short. View Ekso Bionics' Short Interest. When is Ekso Bionics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our EKSO earnings forecast. How were Ekso Bionics' earnings last quarter? Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) posted its earnings results on Monday, November, 1st. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.10. The company earned $3.05 million during the quarter, compared to analysts' expectations of $2.58 million. Ekso Bionics had a negative net margin of 109.88% and a negative trailing twelve-month return on equity of 45.07%. During the same period last year, the business posted ($0.52) EPS. When did Ekso Bionics' stock split? Ekso Bionics's stock reverse split on Thursday, May 5th 2016. The 1-7 reverse split was announced on Wednesday, May 4th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 4th 2016. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split. What other stocks do shareholders of Ekso Bionics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ekso Bionics investors own include Organigram (OGI), Gran Tierra Energy (GTE), KushCo (KSHB), CNBX Pharmaceuticals (CNBX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), Novan (NOVN), Pennsylvania Real Estate Investment Trust (PEI) and ADMA Biologics (ADMA). What is Ekso Bionics' stock symbol? Ekso Bionics trades on the NASDAQ under the ticker symbol "EKSO." Who are Ekso Bionics' major shareholders? Ekso Bionics' stock is owned by many different institutional and retail investors. Top institutional investors include Essex Investment Management Co. LLC (3.38%), Legato Capital Management LLC (0.29%), Strategic Wealth Investment Group LLC (0.22%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jason C Jones, Jerome Wong, John Glenn, Scott G Davis and Steven Sherman. View institutional ownership trends. How do I buy shares of Ekso Bionics? Shares of EKSO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ekso Bionics' stock price today? One share of EKSO stock can currently be purchased for approximately $1.70. How much money does Ekso Bionics make? Ekso Bionics (NASDAQ:EKSO) has a market capitalization of $22.34 million and generates $11.25 million in revenue each year. The company earns $-9,760,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. How can I contact Ekso Bionics? Ekso Bionics' mailing address is 1414 HARBOUR WAY SOUTH SUITE 1201, RICHMOND CA, 94804. The official website for the company is www.eksobionics.com. The company can be reached via phone at (510) 984-1761, via email at investors@eksobionics.com, or via fax at 510-927-2647. This page (NASDAQ:EKSO) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.